Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: Comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab - 14/10/10
Corresponding author. Tel.: +81 95 819 7266; fax: +81 95 849 7270.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept.
Methods |
Forty-five RA patients receiving 25mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables– COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab –were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission.
Results |
Serum COMP correlated with DAS28-ESR (p<0.05, r=0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR<2.6) whereas the other 35 patients did not (DAS28-ESR>2.6). The decrement of serum COMP at 6 months was significant in the remission group (N=10) but not in the non-remission group (N=35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months.
Conclusions |
Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACR, anti-CCP Ab, COMP, CRP, DAS, DMARDs, ESR, RF, MMP-3, PMS, RA, TEMPO, TNF
Keywords : Rheumatoid arthritis, Cartilage oligomeric matrix protein, Etanercept
Plan
Vol 77 - N° 5
P. 418-420 - octobre 2010 Retour au numéro
Article précédent
- TNF
antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis - Marion Couderc, Sarah Payet, Cécile Henquell, Jean-Jacques Dubost, Martin Soubrier
- Gait analysis as a quantifiable outcome measure in hip or knee osteoarthritis: A systematic review
- Paul Ornetti, Jean-Francis Maillefert, Davy Laroche, Claire Morisset, Maxime Dougados, Laure Gossec
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?